Common drug review new combination product : indication: a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults without past or present evidence of viral resistance to Doravirine, Lamivudine, or TenofovirDoravirine/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination (Delstrigo) Merck Canada Inc
Human immunodeficiency virus is responsible for causing HIV infection, a condition that gradually weakens the immune system. HIV is transmitted via body fluids such as blood, semen, genital secretions, and breast milk; most commonly from unprotected sexual intercourse or through sharing of contaminated needles and syringes with an infected person. Left untreated, HIV infection can progress to AIDS and ultimately death. Surveillance data from the Public Health Agency of Canada estimates that, at the end of 2016, there were approximately 84,409 people in Canada living with HIV/AIDS, with an incidence rate of 6.4 per 100,000 population, or 2,344 new reported cases yearly. Since the invention of highly active antiretroviral (ARV) therapy in the mid-1990s, antiretroviral therapy (ART) has improved steadily with the availability of newer potent-combination therapies. Treatments are aimed at lowering the level of HIV in the body, thereby allowing the immune system to recover and respond to other infections. Newer ARTs have significantly reduced HIV-associated morbidity and mortality, and HIV is now largely considered a manageable chronic condition. The following section provides an overview of the evidence pertaining to the studies relevant for this review. This review was conducted in tandem with an evaluation of the DOR single-dose product, Pifeltro, which includes additional study data that are not presented in this report. Readers are therefore suggested to consult the Pifeltro report for additional context..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
June 2019 |
|---|---|
| Erschienen: |
Ottawa (ON): CADTH ; June 2019 |
| Ausgabe: |
Final (with redactions). |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed January 28, 2020) |
|---|
| Umfang: |
1 online resource (1 PDF file (52 pages)). |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
177318945X |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 177318945X | ||
| 003 | DE-627 | ||
| 005 | 20230428011948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)177318945X | ||
| 035 | |a (DE-599)KEP068710291 | ||
| 035 | |a (NCBI)9917538893406676 | ||
| 035 | |a (EBP)068710291 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Common drug review new combination product |b indication: a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults without past or present evidence of viral resistance to Doravirine, Lamivudine, or TenofovirDoravirine/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination (Delstrigo) Merck Canada Inc |
| 250 | |a Final (with redactions). | ||
| 264 | 1 | |a Ottawa (ON) |b CADTH |c June 2019 | |
| 300 | |a 1 online resource (1 PDF file (52 pages)). | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed January 28, 2020) | ||
| 520 | |a Human immunodeficiency virus is responsible for causing HIV infection, a condition that gradually weakens the immune system. HIV is transmitted via body fluids such as blood, semen, genital secretions, and breast milk; most commonly from unprotected sexual intercourse or through sharing of contaminated needles and syringes with an infected person. Left untreated, HIV infection can progress to AIDS and ultimately death. Surveillance data from the Public Health Agency of Canada estimates that, at the end of 2016, there were approximately 84,409 people in Canada living with HIV/AIDS, with an incidence rate of 6.4 per 100,000 population, or 2,344 new reported cases yearly. Since the invention of highly active antiretroviral (ARV) therapy in the mid-1990s, antiretroviral therapy (ART) has improved steadily with the availability of newer potent-combination therapies. Treatments are aimed at lowering the level of HIV in the body, thereby allowing the immune system to recover and respond to other infections. Newer ARTs have significantly reduced HIV-associated morbidity and mortality, and HIV is now largely considered a manageable chronic condition. The following section provides an overview of the evidence pertaining to the studies relevant for this review. This review was conducted in tandem with an evaluation of the DOR single-dose product, Pifeltro, which includes additional study data that are not presented in this report. Readers are therefore suggested to consult the Pifeltro report for additional context. | ||
| 650 | 2 | |a HIV Infections |x drug therapy |0 https://id.nlm.nih.gov/mesh/D015658Q000188 | |
| 650 | 2 | |a Anti-HIV Agents |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D019380Q000627 | |
| 650 | 2 | |a Anti-HIV Agents |x adverse effects |0 https://id.nlm.nih.gov/mesh/D019380Q000009 | |
| 650 | 2 | |a Drug Combinations |0 https://id.nlm.nih.gov/mesh/D004338 | |
| 650 | 2 | |a Comparative Effectiveness Research |0 https://id.nlm.nih.gov/mesh/D057186 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 655 | 2 | |a Systematic Review |0 https://id.nlm.nih.gov/mesh/D000078182 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK544820/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994086442 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994012716 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999788992 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995679102 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987679204 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987765615 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK544820/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK544820/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK544820/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK544820/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK544820/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||